U.S. FDA Issues Warning Letter To Tomita For GMP Deficiencies
This article was originally published in PharmAsia News
Executive Summary
The U.S. FDA issued a Jan. 14 warning letter to Tokushima, Japan-based Tomita Pharmaceutical Co. for "significant deviations" from U.S. current good manufacturing practices in Tomita's manufacturing of active pharmaceutical ingredients